glp-1 in heart failure Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology 📌 Most viewed this week

10.1371/journal.pone.0144829 131 MatysiakM.Kapka-SkrzypczakL.BrzoskaK.GutlebA

Safety and Side Effects Safety data for CJC-1295 come primarily from Phase I/II clinical trials and preclinical studies

Scientific Classification A synthetic triple-receptor agonist peptide targeting GIP, GLP-1, and glucagon receptor families

7 PCC either can be 4-factor-concentrate containing adequate amounts of vitamin K-dependent factors II, VII, IX, and X, or can be 3-factor-concentrate containing lower amounts of factor VII

Some are daily injections while others are weekly

Special Populations Type 2 Diabetes Retatrutide is being studied specifically in people with type 2 diabetes (TRIUMPH-4 trial)